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Background: Data on the current burden of adenocarcinoma (ADC) and histology-specific human papillomavirus
(HPV) type distribution are relevant to predict the future impact of prophylactic HPV vaccines.
Methods: We estimate the proportion of ADC in invasive cervical cancer, the global number of cases of cervical
ADC in 2015, the effect of cervical screening on ADC, the number of ADC cases attributable to high-risk HPV types
-16, -18, -45, -31 and -33, and the potential impact of HPV vaccination using a variety of data sources including:
GLOBOCAN 2008, Cancer Incidence in Five Continents (CI5) Volume IX, cervical screening data from the World
Health Organization/Institut Català d'Oncologia Information Centre on HPV and cervical cancer, and published
literature.
Results: ADC represents 9.4% of all ICC although its contribution varies greatly by country and region. The global
crude incidence rate of cervical ADC in 2015 is estimated at 1.6 cases per 100,000 women, and the projected
worldwide incidence of ADC in 2015 is 56,805 new cases. Current detection rates for HPV DNA in cervical ADC tend
to range around 80–85%; the lower HPV detection rates in cervical ADC versus squamous cell carcinoma may be
due to technical artefacts or to misdiagnosis of endometrial carcinoma as cervical ADC. Published data indicate that
the five most common HPV types found in cervical ADC are HPV-16 (41.6%), -18 (38.7%), -45 (7.0%), -31 (2.2%) and
-33 (2.1%), together comprising 92% of all HPV positive cases. Future projections using 2015 data, assuming 100%
vaccine coverage and a true HPV causal relation of 100%, suggest that vaccines providing protection against
HPV-16/18 may theoretically prevent 79% of new HPV-related ADC cases (44,702 cases annually) and vaccines
additionally providing cross-protection against HPV-31/33/45 may prevent 89% of new HPV-related ADC cases
(50,769 cases annually).
Conclusions: It is predicted that the currently available HPV vaccines will be highly effective in preventing HPV-
related cervical ADC.
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Invasive cervical cancer (ICC) is one of the leading causes
of cancer in women and according to global estimates from
2008, there are approximately 530,000 new cases and
275,000 deaths annually [1]. Cervical cancer incidence and
mortality has been reduced substantially in countries that
have well-developed cervical screening programs [2]. This
decline in incidence is mainly due to the increased* Correspondence: sylvia.m.taylor@gsk.com
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reproduction in any medium, provided the ordetection and effective treatment of early precursors of
squamous cell carcinoma (SCC), which is the most com-
mon histologic variant of cervical cancer. However, the ef-
fectiveness of screening in reducing the incidence of
cervical adenocarcinoma (ADC) (including adenosquamous
carcinoma [ASC]) is less clear, with many studies indicating
that the relative and absolute incidence of ADC has actually
increased, particularly among younger women [3-10]. In
Western countries, with established cervical screening pro-
grams, ADC may represent up to 25% of ICC cases [4,11].l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that of SCC and this may explain the lower rates of detec-
tion of premalignancies during cytologic screening. The
earliest precursor lesions of ADC are more difficult to de-
fine than those of SCC; lesions are more diverse, and inva-
sive ADC is thought to develop particularly from a small
focus of adenocarcinoma in situ (AIS) [7,11,12]. AIS is
more difficult to sample than squamous precancer as it typ-
ically occurs within the endocervical canal and the cyto-
logical and curettage samples obtained can be difficult to
diagnose accurately and reproducibly [11-13]. As a result of
these factors, ADC is often diagnosed at a more advanced
disease stage than SCC, and is generally associated with a
worse prognosis [14-19].
Two prophylactic human papillomavirus (HPV) vaccines
for the prevention of cervical cancer are now available and
licensed in more than 100 countries. In clinical trials, these
vaccines have shown good efficacy against high grade cer-
vical lesions associated with HPV-16 and/or -18 [20-22].
The HPV-16/18 AS04-adjuvanted vaccine (Cervarix®) has
also shown significant type-specific cross-protection for
several non-vaccine oncogenic HPV types, including HPV-
31, -33, -45 and -51, using both virological and histopatho-
logical endpoints [20,23]. For the quadrivalent HPV-6/11/
16/18 vaccine (Gardasil®), significant cross-protection has
also been reported for HPV-31, but not for other oncogenic
HPV types to date [24].
However, no data are currently available regarding the
efficacy of these vaccines specifically against ADC. Al-
though AIS lesions were included within the definition
of high-grade lesions in clinical trials evaluating the effi-
cacy of these vaccines, the number of such lesions was
relatively small [20,25]. Therefore, data on the current
burden of ADC and histology-specific HPV type distri-
bution are relevant to predict the future impact of such
vaccines on ADC.
In this article, we estimate the global burden of disease
due to ADC, investigate the effect of cervical screening
on ADC, summarize data on HPV type-distribution in
ADC and estimate the potential impact of HPV vaccin-
ation on ADC.
Methods
Predicted global burden of disease due to ADC in 2015
The projected number of ADC cases in 2015 was estimated
using data from a number of published sources. Firstly, esti-
mates of ICC cases by country were downloaded from
GLOBOCAN 2008 [1]. Secondly, the proportion of ICC
cases that were histologically confirmed ADC cases was ex-
tracted from previously published registry-specific data
from the International Agency for Research on Cancer
(IARC) Cancer Incidence for Five Continents (CI5) volume
IX [26]. The IARC CI5 data, generally from 1998–2002, are
presented by cancer registry and the majority of countrieshave multiple cancer registries. Where data from multiple
registries per country were available, weighted averages
were calculated to derive country-specific estimates for the
proportion of ADC cases. Country-level proportions were
derived from these weighted averages, and these data were
applied to country-specific ICC cases derived from GLO-
BOCAN. Fewer countries are reported in CI5 than in GLO-
BOCAN 2008 (60 and 182, respectively); thus, countries
were categorized into regions and sub-regions. If country
specific data were not available, other countries within sub-
regions were used to create a weighted average for that
sub-region and these data were applied to all countries in
that sub-region. For example, in the Eastern African sub-
region, data were available for Uganda and Zimbabwe;
these were used to create an Eastern African sub-regional
weighted average which was applied to other countries in
the Eastern African sub-region (e.g., Burundi, Comoros and
Djibouti). Finally, data were then summed to estimate the
total of ADC cases globally in 2015. Crude global incidence
rates for ICC and ADC were calculated from the total
number of cancer cases and the global female population
estimate in 2015 (medium variant) from the United Nations
world population prospects database [27].
In IARC CI5, ASC was categorized as “other” specified
carcinoma rather than ADC, therefore, it was not pos-
sible to estimate the global burden of disease due to
ADC including ASC [26].
Country and regional age-standardized incidence rates of
ADC
Registry-specific age-standardized incidence rates
(ASIRs) of ADC are now published by the IARC in CI5
volume IX [26]. Weighted averages (using the total num-
ber of cases per registry to derive weights) were calcu-
lated to derive country-specific estimates where data on
multiple registries per country were available. Regional
weighted estimates of incidence were then calculated
from country-level data by combining countries within
regions as categorized by IARC.
Effect of cervical screening on ADC
Data on screening coverage rates from cervical screening
programs collated by World Health Organization/Insti-
tut Català d'Oncologia (WHO/ICO) Information Centre
on HPV and Cervical Cancer were used to investigate
whether there was an effect of cervical screening on the
proportion of ADC among ICC cases [28] by country
using linear regression.
Type distribution of HPV in ADC
We summarized the global HPV type distribution in cer-
vical ADC using data from two published sources [29,30].
The first published source was a meta-analysis, performed
by Li and colleagues [29], of HPV type-specific prevalence
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total of 243 studies and 30,848 cases of ICC (3,538 cases of
ADC or ASC). Contributing studies had wide geographic
representation (86 countries), used a variety of PCR-based
technology to detect HPV DNA, and samples came from a
number of sources (fresh or fixed biopsies, or exfoliated
cervical cells). Crude type-specific prevalence for 23 HPV
types in the high-risk clade (HPV-16, -18, -26, -30, -31, -33,
-34, -35, -39, -45, -51, -52, -53, -56, -58, -59, -66, -67, -68,
-69, -70, -73, -82 and -85) [31] and low-risk types HPV-6
and -11 were presented as a proportion of all cases tested,
unadjusted for the impact of multiple types.
The second source was a retrospective cross-sectional
study, performed by de Sanjosé and colleagues, of 10,575
cases of ICC (951 cases of ADC or ASC) paraffin-
embedded tissue blocks collected between 1949 and
2009 from worldwide historic archives in 38 countries
[30]. Although the sample size and geographic represen-
tation is smaller than in the meta-analysis conducted by
Li and colleagues [29], data were included because a
common protocol was used for collection of specimens,
histological confirmation and classification, and HPV
testing (SPF10 broad-spectrum primers [SPF10-DEIA/
LiPA25-polymerase chain reaction (PCR) system
(SPF10-LiPA25; version 1, Labo Biomedical Products,
Rijswijk, The Netherlands, based on licensed Innoge-
netics technology] followed by DNA enzyme immuno-
assay, genotyping with a reverse hybridization line probe
assay and sequencing when required). HPV prevalence
data (19 high-risk and 8 low-risk types) were reported
for those cases which were positive for HPV DNA, and
data analyses included algorithms of multiple infections
to estimate type-specific relative contributions.
Crude data from Li and colleagues were adjusted to fa-
cilitate comparison across the two data sources. Firstly,
data were adjusted so that each HPV type-specific preva-
lence was expressed as a proportion of HPV positive
cases, i.e., each crude estimate was multiplied by 100/82
(as the overall HPV prevalence from this data source
was 82% [29]). Secondly, because women infected with
multiple types contribute several times in the numerator
but only once in the denominator, the addition of the
total percentages exceeded 100%; therefore we also ad-
justed the estimates of prevalence to sum to 100% (i.e.,
the total percentage of all HPV types was 110.7%, so
each estimate of HPV type prevalence was multiplied by
100/110.7). Several studies have established, by laser
capture microscopy and sensitive PCR, that only one
HPV type is found in cancer cells or in a defined area of
precancer even if a whole tissue specimen is positive for
multiple HPV types. Such precise allocation has not
been done in the epidemiological studies reviewed here,
and allocation to an individual HPV type in multiple in-
fections is usually based on its frequency in singleinfections. It is unclear whether this introduces errors
into assessing the causal role of HPV types detected in-
frequently and as multiple infections [32,33].
Finally, to consolidate the HPV-type specific estimates
from these two sources [29,30] into a single estimate for
each type, we took a weighted average based on the total
number of cases of ICC or ADC/ASC in each study.
Potential impact of HPV vaccination
Vaccine efficacies against HPV types -16, -18, -45, -31
and -33 for the two currently available licensed HPV
vaccines (Gardasil® and Cervarix®) were sourced from
published data from double-blind, randomized, con-
trolled, Phase III clinical studies [20,21,23]. In our calcu-
lations we used the point estimate and upper and lower
limits of the confidence intervals for vaccine efficacy
against high-grade cervical lesions (cervical intraepithe-
lial neoplasia grade 2 or higher) associated with each
HPV type. 96.1% and 95.89% confidence intervals were
used for estimates of HPV-16/18 associated vaccine effi-
cacy for Cervarix® and Gardasil®, respectively, due to ad-
justments for multiplicity. 95% confidence intervals were
used for estimates of vaccine efficacy against other HPV
types. Estimates of efficacy from these published sources
were as follows: 98% (86 to 100%) associated with HPV-
16 and -18 [20,21], 100% (42 to 100%) against HPV-45
[23], 89% (66 to 98%) against HPV-31 [23], and 82% (53
to 95%) against HPV-33 [23].
Using the calculated estimates for global burden of
ADC, SCC and ICC in 2015 and the weighted averages
of HPV type distributions [29,30], vaccine efficacy esti-
mates were then used to calculate the proportion and
number of new cases of ADC, SCC and ICC which
could theoretically be prevented by HPV vaccination.
We assumed 100% vaccine coverage in these calcula-
tions. We compared this to SCC, where the proportion
of SCC within total ICC cases was calculated in the
same manner as described for ADC.
Results
Global burden of disease due to ADC
The estimated global crude incidence rates of ICC and
ADC in 2015 are 16.8 cases and 1.6 cases, respectively, per
100,000 women. IARC predicts the worldwide incidence of
ICC in 2015 to be 607,402 cases. It was estimated that
ADC represented 9.4% of all cases of ICC, giving a pre-
dicted worldwide incidence in 2015 of 56,805 cases. The es-
timated proportion of ADC among ICC cases by region
with available data is shown in Figure 1a; this varied from
5.5% in the North African region to 18.7% in Australia/
New Zealand. The majority of the regions classed as more
developed by IARC had a relatively high proportion of
ADC cases (generally >14%), whereas this was more vari-





















Europe (Central & Eastern)
Australia/New Zealand





























0 5 10 15 20





















Europe (Central & Eastern)
Australia/New Zealand































Figure 1 Estimated proportion and number of new cervical ADC cases predicted in 2015 by region. Panel (a) shows estimated proportion
of new cervical ADC cases among total invasive cervical cancer (ICC) cases predicted in 2015 by region. Panel (b) shows estimated number of
new cervical ADC cases predicted in 2015 by region.
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the least developed regions with over half (53%) of the total
ADC cases seen in South and Eastern Asia (Figure 1b).
Age-standardized ADC incidence rates
Country-level ASIRs [26] of ADC were very variable
across countries (Table 1), with incidence per 100,000
women ranging from 0.2 in Algeria (Sétif ) and Tunisia
(Sousse) to 3.2 in Peru (Trujillo) and peaking at 3.4 in
Thailand (3 registries). Within countries with multiple
registries, there was also variability between registries
(Table 1). For example, in China, there was an 8-fold dif-
ference in the minimum and maximum ASIR across 5
registries (ranging from 0.2 to 1.6 per 100,000 respect-
ively) and similarly in Italy, a 5-fold difference was seen
across 22 registries (ranging from 0.3 to 1.5 per 100,000
women). Conversely, other countries were more homo-
geneous and there was no or little difference in ASIR:
Austria [2 registries] no difference; Turkey [2 registries]
and Kuwait [2 registries] with difference of 0.1 per
100,000 women. The highest registry-specific ASIRs
were seen from the Brasilia registry in Brazil (4.5 per
100,000 women) and Lampang in Thailand (3.9 per
100,000 women).
Figure 2 groups the countries with available ASIR data
[26] for ADC into world regions. The incidence of ADC
was markedly highest in Central and South America (2.7
per 100,000 women), followed by Africa (1.5 per 100,000
women) and Asia (1.5 per 100,000 women). For com-
parison, the incidence of SCC in these same regions was
18.1 per 100,000 women in Central and South America,
22.9 per 100,000 women in Africa and 11.3 per 100,000
women in Asia.
Effect of cervical screening on ADC
Information regarding cervical screening coverage was
available from 48 countries (30 developed and 18 devel-
oping, as classified by IARC) of the 61 countries that
had data reported for the proportion of ADC in ICC
(see Figure 3). For these 48 countries (regardless of
whether designated as developed or developing), there
was a slight increasing trend in the percentage of ADC
contributing to ICC with increasing cervical screening
coverage (coefficient of determination [R2] = 0.13). This
trend was not strong and was influenced by Finland
(which has an estimated screening coverage of almost
70% and an estimated percentage ADC of 28.5%). When
developed and developing countries were considered
separately (Figure 3; red circle - developed, blue square -
developing), there was a slight upward trend in percent-
age of ADC with increasing cervical screening coverage
for both developed countries and developing countries,
but the associations were weak (developed countries R2
= 0.06; developing countries R2 = 0.08).Type distribution of HPV in ADC
From the two published studies we investigated (Table 2),
HPV DNA positivity in cases of ADC ranged from
65.6% [30] to 82.0% [29]. The most common HPV types
in cervical ADC were HPV-16 (40.0 to 47.4%), HPV-18
(32.2 to 40.5%) and HPV-45 (5.7 to 11.8%). Based on the
weighted averages from the two data sources, the pro-
portion of all cervical ADCs associated with HPV-16
and/or 18 was approximately 80%. Three HPV types
(HPV-16, -18 and -45) comprised approximately 87% of
all cervical ADCs and five HPV types (HPV-16, -18, -45,
-31 and -33) comprised approximately 92% of all cervical
ADCs.
Potential impact of HPV vaccination
The potential impact of a prophylactic HPV vaccine assum-
ing 100% vaccine coverage is shown in Figure 4. The pre-
ventative potential of an HPV vaccine is slightly greater for
cervical ADC than for SCC: it was estimated that a vaccine
which protects against infection with HPV-16 and -18 may
theoretically prevent 79% (range of estimates calculated
using the lower and upper bound limits of the confidence
intervals from reported efficacy estimates: 69% to 80%) of
new ADC cases and 68% (60 to 69%) of new SCC cases
(Figure 4a). However, as the proportion of SCC cases rela-
tive to ADC cases is much larger, this translates into the
theoretical prevention of 44,702 (39,228 to 45,614) cases of
ADC and 335,143 (294,105 to 341,983) cases of SCC per
year for a vaccine providing protection against HPV-16
and -18 (Figure 4b).
It is estimated that an additional 6,067 cases of ADC
per year and 57,545 cases of SCC per year could be pre-
vented due to cross-protective efficacy against HPV-31,
-33 and -45. This would result in the theoretical preven-
tion of 50,769 (41,931 to 42,356) cases of ADC and
392,688 (321,360 to 327,904) cases of SCC per year for a
vaccine providing protection against HPV-16, -18 -45,
-31 and -33 (Figure 4b).
Discussion
The incidence of cervical ADC is rising and year-on-
year comprises an increasingly larger proportion of all
cervical cancer cases [3]. Using the latest available data,
we estimated that ADC comprises almost a tenth of ICC
globally and that the global burden of ADC is signifi-
cant, reaching almost 60,000 new cases in 2015. Five
HPV types (HPV-16, -18, -45, -31 and -33) together
comprise over 90% of all cervical ADCs. Our data show
that vaccines protective against HPV-16 and -18 could
potentially prevent 44,702 cases (79%) of ADC globally
per year, assuming 100% vaccine coverage. Vaccines with
good cross-protective efficacy against other HPV types,
including -45, -31 and -33, could potentially prevent an
additional 6,067 cases (89%) of ADC globally per year.
Table 1 Age-standardized incidence of cervical ADC by country







Algeria, Sétif (1) 0.20 - -
Egypt, Gharbiah (1) 0.30 - -
Tunisia, Centre, Sousse (1) 0.20 - -
Uganda, Kyadondo County (1) 1.30 - -
Zimbabwe, Harare (1) 2.30 - -
America, Central and South
Argentina, Bahia Blanca (1) 1.30 - -
Brazil (4) 2.98 2.50 4.50
Chile, Valdivia (1) 1.80 - -
Colombia, Cali (1) 2.50 - -
Costa Rica (1) 2.20 - -
Ecuador, Quito (1) 1.80 - -
La Martinique (1) 3.10 - -
Peru, Trujillo (1) 3.20 - -
America, North
Canada2 (10) 1.40 0.9 1.8




Bahrain: Bahraini4 (1) 0.60 - -
China (5) 1.17 0.20 1.60
India (6) 0.89 0.50 1.10
Israel (1) 0.80 - -
Japan (7) 1.05 0.80 1.50
Korea2 (8) 1.40 1.20 2.20
Kuwait (2) 0.44 0.40 0.50
Malaysia (2) 2.63 2.20 2.90
Oman: Omani4 (1) 0.50 - -
Pakistan, South Karachi (1) 0.80 - -
Philippines, Manila (1) 2.20 - -
Singapore (1) 2.00 - -
Thailand (3) 3.44 2.40 3.90
Turkey (2) 0.62 0.60 0.70
Europe
Austria2 (2) 0.90 1.30 1.30
Belarus (1) 0.90 - -
Belgium (2) 1.06 0.90 1.10
Bulgaria (1) 1.30 - -
Croatia (1) 0.90 - -
Cyprus (1) 0.60 - -
Czech Republic (1) 1.30 - -
Denmark (1) 1.70 - -
Estonia (1) 0.80 - -
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Table 1 Age-standardized incidence of cervical ADC by country (Continued)






Finland (data not available) - - -
France (11) 1.00 0.50 1.30
Germany (4) 1.05 0.90 1.30
Iceland (1) 1.60 - -
Italy (22) 1.02 0.30 1.50
Latvia (1) 0.80 - -
Lithuania (1) 1.40 - -
Malta (1) 0.40 - -
Norway (1) 1.60 - -
Poland (2) 0.97 0.90 1.10
Portugal (2) 1.40 1.00 1.70
Russia, St Petersburg (1) 0.80 - -
Serbia (1) 1.70 - -
Slovak Republic (1) 1.40 - -
Slovenia (1) 1.70 - -
Spain (11) 1.10 0.50 1.70
Sweden (1) 1.60 - -
Switzerland (7) 0.94 0.50 1.40
The Netherlands2 (2) 1.10 0.70 1.50
United Kingdom and Eire5 (12) 1.36 1.10 1.60
Oceania
Australia (7) 1.18 1.00 1.30
French Polynesia (1) 1.20 - -
New Zealand (1) 1.20 - -
For countries with a single registry, the age-standardized incidence of cervical ADC for that registry is shown. For countries with multiple registries, the weighted
average age-standardized incidence of ADC is shown. The number in parentheses after each country/city is the number of registries for that region. 1Data from
Cancer Incidence in Five Continents (CI5) Volume IX (reference 26). 2Country level data provided by IARC; range from registry specific data (number of registries);
Canada (10), Korea (8); Austria (2); Netherlands (2). 3National Program of Cancer Registries data used for USA country-level estimate; range from 35 state registries.
4Data provided for a race/ethnic group and not city. 5Includes data from 9 registries in England, 1 in Scotland, 1 in Northern Ireland and 1 in Eire.
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0
Africa (5)





ADC incidence rate per 100,000
Figure 2 Age-standardized incidence of cervical ADC by region.
Each bar represents the weighted average age-standardized
incidence of cervical ADC for that region. Error bars show minimum
and maximum values for individual countries within a region.
Number in parentheses after region indicates number of countries
contributing data. Incidence rates calculated using data from Cancer
Incidence in Five Continents (CI5) Volume IX [reference 26].
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rates of ADC were very variable between regions and
countries, and even within countries. It is known that there
is variation in the pathological diagnosis of histological
types of ICC between diagnostic centres and diagnosis may
be recorded in different ways in medical records. Other
studies have noted wide intra-observation between colpos-
copists and pathologists in the ability to correctly identify
morphologically diverse ADC [11,12]. ADC and SCC seem
to share similar risk factors such as number of sexual part-
ners, age at first sexual intercourse and use of oral contra-
ceptive, but differ by parity, tobacco smoking and obesity
[9,34-36] and it is likely that distribution of these risk fac-
tors differ by country/region. Variation in type-specific
HPV prevalence may also be a contributing factor to the
differences observed between countries [37]. Additionally,
cervical screening may be more effective in detecting SCC

















Figure 3 Estimated percentage of cervical ADC versus estimated
percentage of cervical screening coverage. Red circle, developed
countries; blue square, developing countries; red dashed line = trend
line for developed countries; blue solid line = trend line for developing
countries; R2, coefficient of determination. R2 for all countries
(regardless of whether designated as developed or developing) = 0.13.
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higher proportion of ADC in ICC, however, our data were
too limited to draw any firm conclusions as evidenced by
the low correlation coefficients reported.
In the two data sources we selected, HPV DNA positiv-
ity in cases of ADC (including ASC) were 65.6% [30] and
82.0% [29], respectively. The relatively large proportion of
HPV negative cases in the de Sanjosé study occurred des-
pite the use of the highly sensitive SPF10 system for detec-
tion of HPV in formalin-fixed paraffin-embedded tissue
and, according to the study authors, was likely due to
technical artefacts, including tissue degradation (since this
study reassessed samples archived as far back as 1949)
and low viral load [30]. Li and colleagues did a meta-
analysis of data from different studies published from
1990 to 2010 [29], which included a mix of fresh/fixed bi-
opsies or exfoliated cells and prospective and retrospective
testing using SPF10 and other less sensitive PCR based de-
tection methods [39-41].
The low HPV detection rates may also be partly attrib-
uted to misdiagnosis of endometrial carcinoma as cervical
ADC [42,43], but even in studies with careful histopatho-
logical review detection rates for ADC tend to range
around 80-85% compared with 90-95% for SCC [44,45].
Unlike SCC which is generally acknowledged to be 100%
attributable to HPV, some small proportion of rare histo-
logical variants of ADC (nonmucinous adenocarcinomas
including clear cell, serous, and mesonephric carcinomas)
likely arise independently of exposure to HPV [46,47]. The
lower HPV detection rates for ADC versus SCC may be at-
tributable to higher susceptibility of cervical ADC tissue to
DNA degradation, due to lower DNA copy number forexample, but this remains unclear and needs to be further
investigated. There is also some evidence that HPV detec-
tion in cervical ADC may be improved by targeting of early
protein E6 rather than the L1 segments that are targeted by
SPF10 [48,49].
If any falsely HPV DNA negative samples were attrib-
utable to a particular HPV type, the missing HPV types
could theoretically bias the overall HPV type distribution
[30]. Although this possibility cannot be ignored, the
HPV type distribution in ADC (including ASC) was gen-
erally similar across both data sources, with HPV-16 and
-18 being the most common types, followed by HPV-45
and then HPV-31 and -33 [29,30]. Any observed differ-
ences in HPV type distribution across the two data
sources may be due to geographical variation, though it
was not possible for us to quantify such differences as
type-distribution data for ADC/ASC were not broken
down by geographic region.
HPV types are traditionally grouped into phylogenetic-
ally-related species based on the genetic similarity of their
L1 genes [50]. High-risk HPV types that cause cervical can-
cer fall largely, though not exclusively, within the Alpha-
papillomavirus 9 (alpha-9) species characterized by HPV-
16 and including types -31, -33, -35, -52 and -58 and the
alpha-7 species characterized by HPV-18 and including
types -39, -45, -59 and -68 [51]. It is well documented that
progression to SCC is greater for HPV-16 than HPV-18,
but that HPV-18 is over-represented in ADC compared to
SCC [52]. Both data sources used in our analysis confirm
the limited genotype distribution among ADC, and the
relatively high contribution of alpha-7 species such as
HPV-18 and HPV-45. The greater tendency of alpha-7 spe-
cies to cause ADC compared to alpha-9 and other species
could be due to a phylogenetic trait, such as a greater trop-
ism for infection of cervical glandular tissue or the multipo-
tential cells of the squamocolumnar junction, and/or a
better ability to neoplastically transform glandular cells
once an infection is established [52,53].
The incidence of multiple infections amongst overall ICC
was comparable in both data sources (7% in the meta-
analysis [29] and 11.2% in the cross-sectional analysis [30]).
Additionally, the incidence of multiple infections was simi-
lar between SCC and ADC (only the meta-analysis pro-
vided these data). The effect of multiple infections with
respect to attribution to ICC and vaccine efficacy is
unknown.
Prophylactic HPV vaccination has the potential to
prevent a higher proportion of ADC cases than SCC
cases, but the absolute number of ADC cases is still
very small compared to the number of SCC cases.
Our data show that vaccines protective against
HPV-16, -18, -45, -31 and -33 could potentially pre-
vent 89% of HPV-related ADC cases, accounting for
50,769 cases of ADC globally per year, assuming
Table 2 Global HPV type distribution in cervical ADC (including ASC)
HPV type Li et al., 20111 de Sanjosé et al., 20102 Weighted average of both studies
Number of cases 35253 951 -
HPV positive cases, n (%) 2891 (82.0%) 624 (65.6%) -
HPV prevalence among HPV positive cases (%)
6 0.1 0.2 0.1
11 0.1 0.0 0.1
16 40.0 47.4 41.6
18 40.5 32.2 38.7
26 0.0 0.0 0.0
30 0.0 0.2 0.0
31 2.5 1.0 2.2
33 2.4 1.0 2.1
34 0.0 0.0 0.0
35 0.7 0.6 0.7
39 0.9 0.8 0.9
40 NT 0.0 -
42 NT 0.0 -
43 NT 0.0 -
44 NT 0.0 -
45 5.7 11.8 7.0
51 0.7 0.6 0.7
52 1.3 0.2 1.1
53 0.2 0.2 0.2
54 NT 0.0 -
56 0.2 0.3 0.2
58 1.7 0.5 1.4
59 0.9 0.8 0.9
66 0.1 0.2 0.1
67 0.2 0.0 0.2
68 0.6 0.3 0.5
69 0.9 0.0 0.7
70 0.2 0.0 0.2
73 0.0 0.0 0.0
74 NT 0.0 -
82 0.1 NT -
85 0.0 NT -
Undetermined NR 1.3 -
ADC, adenocarcinoma; ASC, adenosquamous carcinoma; NR, not reported; NT, not tested. 1We adjusted prevalence rates from those reported by Li et al. [29] to
indicate the HPV type-specific contribution to the total number of positive samples. In addition because women infected with multiple types contribute multiple
times in the numerator but only once in the denominator, the addition of the total percentages exceeded 100; therefore we also adjusted these estimates to sum
to 100%. 2de Sanjosé et al. [30] reported prevalence rates for ADC and ASC separately; we have added the estimates together to give an estimate of type-specific
prevalence for ADC (including ASC). Prevalence rates indicate the HPV type-specific contribution to the total number of positive samples. Multiple infections were
added to single types through proportional weighting attribution. 3HPV positivity data reported for only 3,525 of the 3,538 total cases of ADC.
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http://www.biomedcentral.com/1471-2407/13/553100% vaccine coverage and a true HPV causal relation
of 100%.
Our predictions do have some limitations and caveats. In
estimating the potential impact of prophylactic HPVvaccines on cervical ADC, we assumed that 100% of ADC
cases were due to HPV. However, we recognize that it is
likely that although the vast majority (80% or more) [29] of



































































Number of cases prevented per year
(b) Vaccine against:
Figure 4 Theoretical global impact of prophylactic HPV vaccination on cervical ADC, SCC and ICC. Panel (a) and panel (b) show future
predictions, using 2015 data, of the proportion of new cases and number of new cases, respectively, of ADC (including ASC), SCC and ICC which
could theoretically be prevented globally by a HPV vaccine efficacious against HPV-16/18, HPV-16/18/45 or HPV-16/18/45/31/33. Each bar repre-
sents the point estimate. The numbers to the right of each bar are the actual point estimates. The error bars represent the corresponding range
of estimates calculated using the lower and upper bound limits of the confidence intervals from reported efficacy estimates (96.1% and 95.89%
confidence intervals were used for estimates of HPV-16/18 associated vaccine efficacy for Cervarix® and Gardasil®, respectively, due to adjustments
for multiplicity. 95% confidence intervals were used for estimates of vaccine efficacy against other HPV types). We assumed 100% vaccine cover-
age in these calculations.
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http://www.biomedcentral.com/1471-2407/13/553caused by oncogenic HPV, a small proportion of such cases,
especially those in the less frequent histological subtypes,
are probably not associated with HPV [46,54,55] and we
may, therefore, have overestimated the impact of HPV vac-
cination in preventing ADC. We did not specifically look at
the role of multiple infections in ADC and the role of indi-
vidual HPV types in causing cancer in multiple infections.
We did not investigate the role of future changes in HPV
infection rates. Additionally, as we wanted to investigate
the potential benefit of HPV vaccination, we assumed that
vaccine coverage was 100%, although we recognize that
vaccine coverage may be much lower, particularly in less
developed countries in which the burden of disease is
highest.
Conclusions
Prevention of cervical ADC through detection of pre-
neoplastic stages has proved to be largely unsatisfactory,as observed by the high proportion of ADC in well-
screened populations. We predict that the currently
available HPV vaccines will be highly effective in pre-
venting cervical HPV-related ADC. Extended protection
against HPV-45, -31 and -33 would also be of benefit.
Cervarix is a registered trade mark of the GlaxoSmithKline
group of companies.
Gardasil is a registered trade mark of Merck & Co
Inc.
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